Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
Myris Therapeutics emerges from stealth to announce new name and strategic focusProprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 - 100 and new chemical space for precision